Crinetics Pharmaceuticals trades at a steep discount while maintaining strong analyst support and a ~$3B valuation. Learn why ...

National registries of patients with acromegaly have been created, enabling future study of disease outcome and testing of new treatments. 8,9 In addition, highly sensitive and specific growth ...

PGIMER's Groundbreaking Surgery Reshapes Lives of Acromegaly Patients The Department of Neurosurgery at PGIMER successfully treated a rare case of acromegaly in a 35-year-old police head constable ...

Sixty patients with active acromegaly received octreotide 100 μg three times daily for 28 days and then pasireotide at 200 μg, 400 μg and 600 μg twice daily in random order, each for 28 days.

Camurus (NASDAQ STO: CAMX) today announced topline results from the 12-month, randomized, double-blind, placebo-controlled POSITANO Phase ...

Camurus announces positive results from POSITANO phase 2b study of octreotide SC depot in patients with symptomatic polycystic liver disease: Lund, Sweden Thursday, June 19, 2025, ...

UK study suggests that patients with prolactinoma treated with dopamine agonists are more likely to develop impulse control disorders ...

CAM2029 reduces liver and cyst volume growth compared to placebo Well tolerated with no new or unexpected safety findingsA follow-up Phase 3 study will be discussed with regulatory authoritiesLUND ...

“It’s absolutely insane to try to keep up with it all.” Across the country, doctors who treat patients for obesity are being forced to develop what amounts to a subspecialty in navigating ...

AACE released clinical guidelines on the diagnosis, management, and surveillance of tumors related to multiple endocrine neoplasia type 1.

Diagnosed with early-stage lung cancer, she is among the first patients in China to receive the LK101 injection – a personalised mRNA vaccine designed to slash the risk of relapse. Lecheng ...

Doctors can test for the deficiency — and then either switch drugs or lower the dosage if patients have a genetic variant that carries risk. The FDA approved an antidote in 2015, but it’s ...